SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)
Completed · Phase 4 · Has a placebo group
Conditions studied: Open-Angle Glaucoma, Ocular Hypertension
In brief
The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of brinzolamide 1%/brimonidine 0.2% (dosed twice per day (BID)) when added to a prostaglandin analogue (PGA) in subjects with open-angle glaucoma or ocular hypertension.
Key facts
- Study ID
- NCT02419508
- Run by
- Alcon Research
- People needed
- 290
- Starts
- 2015-08-07
- Expected to finish
- 2018-02-27
- Last updated by the study team
- 2018-11-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosis of either open-angle glaucoma or ocular hypertension;
- Must sign an informed consent form;
- Mean IOP measurements at both the Eligibility 1 and 2 visits, in at least 1 eye (the same eye[s]) ≥ 19 and < 32 mmHg at 09:00.
- Willing and able to attend all study visits;
- Other protocol-specified inclusion criteria may apply.
You may not qualify if…
- Women of childbearing potential who are pregnant, breast-feeding, intend to become pregnant during the study, or not using adequate birth control methods to prevent pregnancy throughout the study;
- Any form of glaucoma other than open-angle glaucoma or ocular hypertension;
- Ocular disease, trauma, infection, inflammation, pathology, or surgery as specified in the protocol;
- Any other conditions including severe illness which would make the subject, in the opinion of the Investigator, unsuitable for the study;
- Other protocol-specified exclusion criteria may apply.
Where it is running
- Contact Alcon Call Center for Trial Locations — Fort Worth, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.